X4 Pharmaceuticals, Inc (XFOR) — 8-K Filings

8-K Filings (24)

• X4 Pharmaceuticals Enters Material Definitive Agreement — Oct 27, 2025 Risk: medium
  On October 23, 2025, X4 Pharmaceuticals, Inc. entered into a material definitive agreement. The company, formerly known as Arsanis, Inc., is incorporated in Del
• X4 Pharmaceuticals Files 8-K on Exit Costs and Personnel Changes — Sep 17, 2025 Risk: medium
  On September 15, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report detailing cost associated with exit or disposal activities, departure of directors or certai
• X4 Pharmaceuticals Announces Director and Officer Changes — Aug 25, 2025 Risk: medium
  On August 22, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates th
• X4 Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Aug 13, 2025 Risk: medium
  On August 12, 2025, X4 Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• X4 Pharmaceuticals Files 8-K: Agreements, Equity Sales, Officer Changes — Aug 12, 2025 Risk: medium
  On August 11, 2025, X4 Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• X4 Pharmaceuticals Files 8-K: Material Agreement & Exhibits — Jun 23, 2025 Risk: medium
  On June 23, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statem
• X4 Pharmaceuticals Files 8-K on Security Holder Vote Matters — Jun 11, 2025 Risk: low
  On June 11, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing date for the earliest
• X4 Pharmaceuticals Changes Fiscal Year End — Apr 24, 2025 Risk: low
  On April 24, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's fiscal year end to December 31st. Previously, th
• X4 Pharmaceuticals Files 8-K on Security Holder Vote — Apr 18, 2025 Risk: low
  X4 Pharmaceuticals, Inc. filed an 8-K on April 18, 2025, reporting on a matter submitted to a vote of its security holders on April 17, 2025. The company, forme
• X4 Pharmaceuticals Files 8-K on Operations — Mar 25, 2025 Risk: low
  X4 Pharmaceuticals, Inc. filed an 8-K on March 25, 2025, reporting on its financial condition and operations. The company, formerly known as Arsanis, Inc., is b
• X4 Pharmaceuticals Updates Principal Executive Offices — Mar 3, 2025 Risk: low
  On March 3, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 61 North Beacon St
• X4 Pharmaceuticals Files 8-K on Exit Activities — Feb 6, 2025 Risk: medium
  On February 6, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates activities related to cost associated with exit or disposal activities,
• X4 Pharmaceuticals Files 8-K: Material Agreement, Financials — Jan 13, 2025 Risk: medium
  On January 13, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures
• X4 Pharmaceuticals Faces Delisting Concerns — Aug 16, 2024 Risk: high
  X4 Pharmaceuticals, Inc. filed an 8-K on August 16, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly
• X4 Pharmaceuticals Files 8-K for Regulation FD Disclosure — Aug 9, 2024 Risk: medium
  X4 Pharmaceuticals, Inc. filed an 8-K on August 9, 2024, reporting a Regulation FD Disclosure as of August 8, 2024. The filing does not contain specific details
• X4 Pharmaceuticals Files 8-K Report — Jul 19, 2024 Risk: low
  On July 19, 2024, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company is based in Boston, Massachusetts, and operates in the biologic
• X4 Pharmaceuticals Files 8-K Report — Jun 27, 2024 Risk: low
  On June 27, 2024, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific m
• X4 Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 11, 2024 Risk: low
  X4 Pharmaceuticals, Inc. filed an 8-K on June 11, 2024, reporting on matters submitted to a vote of security holders as of June 10, 2024. The company, formerly
• X4 Pharmaceuticals Files 8-K — May 22, 2024 Risk: low
  X4 Pharmaceuticals, Inc. filed an 8-K on May 22, 2024, reporting on events that occurred on the same date. The filing primarily concerns financial statements an
• X4 Pharmaceuticals Acquired by Bio-Thera Solutions Subsidiary — May 9, 2024 Risk: low
  On May 8, 2024, X4 Pharmaceuticals, Inc. announced the completion of its acquisition by a subsidiary of Bio-Thera Solutions, Ltd. The transaction was approved b
• X4 Pharmaceuticals Files 8-K Report — Apr 29, 2024 Risk: low
  On April 29, 2024, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
• X4 Pharmaceuticals Files 8-K Report — Apr 5, 2024 Risk: medium
  On April 5, 2024, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is locat
• X4 Pharmaceuticals Files 8-K Report — Apr 1, 2024 Risk: low
  On April 1, 2024, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 61 North Beacon St
• X4 Pharmaceuticals Files 8-K for Regulation FD Disclosure — Jan 8, 2024
  X4 Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, under Regulation FD Disclosure, indicating they are making a public announcement of material non-publi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX